Related Experiment Video

Updated: Jul 14, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K

T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer

David Killock1

  • 1Nature Reviews Clinical Oncology, . d.killock@nature.com.

Nature Reviews. Clinical Oncology
|November 10, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K

Related Experiment Videos

Last Updated: Jul 14, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

TNIK: A redox sensor in endothelial cell permeability.

Science advances·2024

Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.

Nature reviews. Clinical oncology·2026

Exploring the landscape of targetable alterations in patients with glioblastoma.

Nature reviews. Clinical oncology·2026

AI-based augmentation of oncology clinical trials.

Nature reviews. Clinical oncology·2026

Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.

Nature reviews. Clinical oncology·2026

De-escalation trials in multiple myeloma: past, present and future.

Nature reviews. Clinical oncology·2026

Towards liquid biopsy-based analysis of antitumour immunity.

Nature reviews. Clinical oncology·2026

Immune Cell Engager Therapy for Brain Cancer.

Neuro-oncology·2026

Gut microbiota-mediated dietary lignans metabolism drives accumulation of N,N-dimethylsphingosine and sensitizes triple-negative breast cancer to paclitaxel.

Food & function·2026

Ocular Microcystic Adnexal Carcinoma With High-Grade Features: A Case Report With Orbital Exenteration.

International journal of surgical pathology·2026

Effect of photobiomodulation therapy on regulating reparative processes of chronic wounds at the inflammation stage.

Biomedica : revista del Instituto Nacional de Salud·2026

Doxorubicin and 4-Hydroperoxycyclophosphamide Alter Mitochondrial Dynamics and miR-34 Expression in Spermatogonia and Spermatocytes In Vitro.

Basic & clinical pharmacology & toxicology·2026

Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma.

Current opinion in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us